Immunotherapy plus chemo for advanced cervical cancer
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a new treatment that combines an immunotherapy drug (cadonilimab) with chemotherapy for people with locally advanced cervical cancer. The goal is to see if this combination can shrink the tumor enough to make surgery possible or more effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have cervical cancer that has not spread far and has not been treated yet.
- Your tumor is larger than 4 cm and is a type called squamous cell, adenocarcinoma, or adenosquamous carcinoma.
- You are between 18 and 75 years old.
- You are healthy enough for a hysterectomy (surgery to remove the uterus).
- You have not had previous treatment for this cancer, and you have not had immunotherapy before.
- You are not pregnant and agree to use effective birth control during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether adding immunotherapy to chemotherapy, then giving chemotherapy together with radiation, works better for advanced cervical cancer. It aims to improve cancer control and help people live longer, without major safety issues.
This trial tests if giving chemotherapy plus an immunotherapy drug before surgery can help shrink tumors and improve outcomes for patients with stage IB2 cervical cancer that has not been treated yet. It might be an option if you have a specific type of cervical cancer that shows a certain protein (PD-L1) on your tumor cells.
This Phase 2 trial tests cadonilimab (an immunotherapy medicine) combined with anlotinib (a targeted drug) for advanced or recurrent cervical cancer that has already been treated. It may help shrink tumors or slow cancer growth, especially if the cancer has a measurable area doctors can track.
This trial tests whether adding an immunotherapy drug called Cadonilimab (AK104) to standard chemoradiation can help people with locally advanced cervical cancer that has not spread to distant organs. The goal is to improve treatment outcomes for those who cannot have surgery.
This trial tests giving a combination of an immunotherapy drug (QL1706) and two chemotherapy drugs (cisplatin and paclitaxel) before surgery for cervical cancer. The goal is to shrink the tumor to make surgery more effective and improve outcomes.
This trial tests whether a combination of chemotherapy and immunotherapy (pembrolizumab) before surgery works better than standard chemoradiation for locally advanced cervical cancer. It may help shrink tumors more effectively.
Hear when a new Cervical Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.